Universal Vaccine Powerhouse: Centivax Raises $37 Million to Redefine Immunity
March 31, 2026, 9:35 pm
Structure Fund
Location: United States, California, Los Angeles
Centivax secured $37M, pushing its universal flu vaccine, Centi-Flu 01, towards Phase 2 trials. This capital also accelerates four more universal immunity programs: cancer therapy, malaria vaccine, antivenom, and Alzheimer's prevention. A scalable, cell-free manufacturing process is simultaneously advancing for wider reach. This major oversubscribed funding round, led by Structure Fund and backed by tech titans, affirms strong investor belief in Centivax's platform. The company targets broad, durable protection, moving beyond seasonal and specific treatments to reshape global health solutions with lasting impact.
Centivax, a South San Francisco biotechnology firm, just closed an oversubscribed $37 million funding round. This significant capital infusion propels its groundbreaking universal immunity platform forward. The primary focus: accelerating the lead universal influenza vaccine candidate, Centi-Flu 01, into Phase 2 clinical development. The company’s ambitions stretch further. It aims to advance a robust pipeline of additional universal immunity programs.
Investment leaders included Structure Fund. Other participants were Meiji Seika Pharma Co., Sigmas Group, and Kendall Capital Partners. Noteworthy support also came from Stripe founders Patrick and John Collison. This new funding builds on a successful $45 million Series A round completed in June 2025. Such sustained investment signals robust confidence in Centivax’s innovative approach.
The cornerstone of Centivax’s platform is Centi-Flu 01. This universal influenza vaccine targets conserved viral regions. These regions resist mutation, unlike those targeted by traditional seasonal flu shots. Conventional vaccines require annual reformulation. Their effectiveness varies widely, often between 10% and 60%. Centi-Flu 01 promises broad, durable protection. It aims to cover multiple influenza strains. This includes potential pandemic variants. Such a development could revolutionize flu prevention.
Clinical progress is swift. Centivax initiated Phase 1 clinical trials earlier this year. Participant enrollment for the initial cohort is nearly complete. Safety and efficacy across a wide panel of influenza strains are under assessment. Results are expected in 2026. A larger 500-subject Phase 2 trial is slated for early 2027. This trial will evaluate immune response breadth. It will also compare performance against existing vaccines. This aggressive timeline underscores the company’s commitment to rapid innovation.
Centivax’s vision extends beyond influenza. The new funding fuels four additional programs. These emerge from its universal immunity platform. A cancer therapy is in development. A malaria vaccine represents another key effort. A universal antivenom program seeks to address critical unmet needs. Finally, an Alzheimer’s preventative approach shows immense promise. These diverse programs are now preparing for manufacturing and clinical readiness. This demonstrates the platform’s versatility. It holds potential for numerous chronic and infectious conditions.
Manufacturing innovation is central to Centivax’s strategy. The company plans to deploy a scalable, cell-free manufacturing process. This will enter Good Manufacturing Practice (GMP) in 2026. This advanced approach promises reduced production time. It also aims for lower costs. These efficiencies are crucial. They will support later-stage clinical trials. They are vital for broader commercialization efforts. Centivax seeks to control its production means. This ensures agility and independence.
The company’s underlying platform technology has already garnered significant non-dilutive funding. Support comes from prestigious organizations. The Bill and Melinda Gates Foundation is a key backer. The U.S. Department of Defense (DOD), the Army, and the Navy have also contributed. The National Institutes of Health (NIH) provides additional funding. This external validation reinforces the scientific rigor behind Centivax’s universal immunity concept. It confirms the platform’s proof-of-concept.
Centivax, led by Chief Executive Officer Jacob Glanville, focuses on delivering universal protection. Its therapies and vaccines target a wide array of diseases. These span infectious diseases and chronic conditions. The collaboration with Emery Pharma in 2025 further strengthens its operational capabilities. Emery Pharma specializes in GLP/CGMP compliant solutions for analytical and bioanalytical testing. This partnership enhances Centivax’s ability to meet rigorous regulatory standards.
The current bioscience funding landscape is challenging. Many companies face slowdowns or consolidation. Centivax’s ability to secure an oversubscribed financing round stands out. It highlights the strength of its programs. It validates its leadership position. The rapid progression to Phase 2 strengthens its business development stance. It allows unhindered movement through value-driving milestones. This reduces operational constraints linked to seasonal cycles. Clinical readiness now dictates advancement.
Centivax is not just developing new vaccines. It is building a paradigm shift in immunology. Its universal immunity platform targets the core mechanisms of protection. This offers lasting, broad-spectrum defense. From seasonal threats like influenza to complex challenges like cancer and Alzheimer's, the approach promises transformative solutions. The company is poised to make a profound impact on global health. This $37 million investment marks a pivotal step in that journey. Centivax is redefining how humanity fights disease.
Centivax, a South San Francisco biotechnology firm, just closed an oversubscribed $37 million funding round. This significant capital infusion propels its groundbreaking universal immunity platform forward. The primary focus: accelerating the lead universal influenza vaccine candidate, Centi-Flu 01, into Phase 2 clinical development. The company’s ambitions stretch further. It aims to advance a robust pipeline of additional universal immunity programs.
Investment leaders included Structure Fund. Other participants were Meiji Seika Pharma Co., Sigmas Group, and Kendall Capital Partners. Noteworthy support also came from Stripe founders Patrick and John Collison. This new funding builds on a successful $45 million Series A round completed in June 2025. Such sustained investment signals robust confidence in Centivax’s innovative approach.
The cornerstone of Centivax’s platform is Centi-Flu 01. This universal influenza vaccine targets conserved viral regions. These regions resist mutation, unlike those targeted by traditional seasonal flu shots. Conventional vaccines require annual reformulation. Their effectiveness varies widely, often between 10% and 60%. Centi-Flu 01 promises broad, durable protection. It aims to cover multiple influenza strains. This includes potential pandemic variants. Such a development could revolutionize flu prevention.
Clinical progress is swift. Centivax initiated Phase 1 clinical trials earlier this year. Participant enrollment for the initial cohort is nearly complete. Safety and efficacy across a wide panel of influenza strains are under assessment. Results are expected in 2026. A larger 500-subject Phase 2 trial is slated for early 2027. This trial will evaluate immune response breadth. It will also compare performance against existing vaccines. This aggressive timeline underscores the company’s commitment to rapid innovation.
Centivax’s vision extends beyond influenza. The new funding fuels four additional programs. These emerge from its universal immunity platform. A cancer therapy is in development. A malaria vaccine represents another key effort. A universal antivenom program seeks to address critical unmet needs. Finally, an Alzheimer’s preventative approach shows immense promise. These diverse programs are now preparing for manufacturing and clinical readiness. This demonstrates the platform’s versatility. It holds potential for numerous chronic and infectious conditions.
Manufacturing innovation is central to Centivax’s strategy. The company plans to deploy a scalable, cell-free manufacturing process. This will enter Good Manufacturing Practice (GMP) in 2026. This advanced approach promises reduced production time. It also aims for lower costs. These efficiencies are crucial. They will support later-stage clinical trials. They are vital for broader commercialization efforts. Centivax seeks to control its production means. This ensures agility and independence.
The company’s underlying platform technology has already garnered significant non-dilutive funding. Support comes from prestigious organizations. The Bill and Melinda Gates Foundation is a key backer. The U.S. Department of Defense (DOD), the Army, and the Navy have also contributed. The National Institutes of Health (NIH) provides additional funding. This external validation reinforces the scientific rigor behind Centivax’s universal immunity concept. It confirms the platform’s proof-of-concept.
Centivax, led by Chief Executive Officer Jacob Glanville, focuses on delivering universal protection. Its therapies and vaccines target a wide array of diseases. These span infectious diseases and chronic conditions. The collaboration with Emery Pharma in 2025 further strengthens its operational capabilities. Emery Pharma specializes in GLP/CGMP compliant solutions for analytical and bioanalytical testing. This partnership enhances Centivax’s ability to meet rigorous regulatory standards.
The current bioscience funding landscape is challenging. Many companies face slowdowns or consolidation. Centivax’s ability to secure an oversubscribed financing round stands out. It highlights the strength of its programs. It validates its leadership position. The rapid progression to Phase 2 strengthens its business development stance. It allows unhindered movement through value-driving milestones. This reduces operational constraints linked to seasonal cycles. Clinical readiness now dictates advancement.
Centivax is not just developing new vaccines. It is building a paradigm shift in immunology. Its universal immunity platform targets the core mechanisms of protection. This offers lasting, broad-spectrum defense. From seasonal threats like influenza to complex challenges like cancer and Alzheimer's, the approach promises transformative solutions. The company is poised to make a profound impact on global health. This $37 million investment marks a pivotal step in that journey. Centivax is redefining how humanity fights disease.